Share on StockTwits

Athersys (NASDAQ:ATHX) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a report released on Monday. The firm currently has a $1.80 target price on the stock. Zacks‘s price target would suggest a potential upside of 9.09% from the company’s current price.

ATHX has been the subject of a number of other recent research reports. Analysts at Edison Investment Research reiterated a “neutral” rating on shares of Athersys in a research note on Tuesday, May 6th. Analysts at First Analysis initiated coverage on shares of Athersys in a research note on Tuesday, April 29th. They set an “overweight” rating and a $5.00 price target on the stock.

Shares of Athersys (NASDAQ:ATHX) remained flat at $1.80 during during mid-day trading trading on Monday. The stock had a trading volume of 641,108 shares. Athersys has a 52-week low of $1.08 and a 52-week high of $4.33. The stock has a 50-day moving average of $1.58 and a 200-day moving average of $2.75. The company’s market cap is $138.7 million.

Athersys (NASDAQ:ATHX) last announced its earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.66 million. The company’s revenue for the quarter was up 116.9% on a year-over-year basis. On average, analysts predict that Athersys will post $-0.40 earnings per share for the current fiscal year.

Athersys, Inc is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.